It's easy to be skeptical about the prospects for a sustainable biopharma industry in Europe: VC financing is only a sixth of that in the US, and is becoming conditional on marketed, or near-to-market products. IPOs are few and far between, and performing shakily. Drug prices are being slashed, along with reimbursement levels, US acquirers are on the prowl, and increasing numbers of European firms are setting up subsidiaries in the US—in some cases as a prelude to transferring their operations there. (See "European Financing: the Money's There, But How Do You Get It?" this issue [A#2004600086], and "The US: To Go or Not to Go?" this issue.[A#2004600086])
But Europe's challenges are surmountable, according to a group of senior industry executives and experts gathered at Windhover's Euro-Biotech Forum...




